Intercept Pharmaceuticals Raises $25M Series B Financing
Intercept Pharmaceuticals, Inc., a New York-based clinical stage biopharmaceutical company developing novel therapeutics for chronic fibrotic and metabolic diseases, completed a $25m Preferred Series B financing by its majority shareholder Genextra S.p.A. The company’s most advanced programs are focused on the development of modified bile acids that are selective for FXR, a nuclear receptor, and […]